Governance Tenaya Therapeutics, Inc.

TNYA

US87990A1060

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-07-16 pm EDT			5-day change	1st Jan Change
0.8376 ^USD	-0.66%		-1.46%	+17.72%

Jun. 29	Tenaya Therapeutics, Inc. Announces Management Changes, Effective July 13, 2026	CI
Jun. 29	Tenaya Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective July 13, 2026	CI

Executive Committee: Tenaya Therapeutics, Inc.

Manager

Positions heldSince

Faraz Ali

53 year

Chief Executive Officer	2018-05-31
President	-

Jennifer Rokovich

General Counsel	2022-01-09
Corporate Secretary	-

Joanna Auch

Human Resources Officer

2021-12-21

Kee-Hong Kim

Chief Tech/Sci/R&D Officer

2018-09-30

Whittemore Tingley

58 year

Chief Tech/Sci/R&D Officer

2018-11-30

Eric Hyllengren

51 year

Comptroller/Controller/Auditor	2026-07-12
Director of Finance/CFO	2026-07-12

Michelle Corral

Investor Relations Contact	-
Public Communications Contact	-

Matthew Jay Pollman

Chief Tech/Sci/R&D Officer

Kathy Ivey

Chief Tech/Sci/R&D Officer

2024-06-26

Composition of the Board of Directors: Tenaya Therapeutics, Inc.

Director

CommitteesSince

Robert Williams

77 year

Governance Committee
Nominating Committee

June Lee

60 year

Compensation Committee	2020-12-08
Governance Committee	2020-12-08
Nominating Committee	2020-12-08
Compensation Committee Chair	2023-07-10
Nominating Committee Chair	2023-07-10

Karah Parschauer

48 year

Compensation Committee
Governance Committee Chair	2020-04-14
Nominating Committee Chair	2020-04-14
Audit Committee	2021-12-21

Deepak Srivastava

59 year

Governance Committee Chair	2016-09-30
Nominating Committee Chair	2016-09-30

Jeffrey Walsh

60 year

Compensation Committee	2020-02-29
Audit Committee Chair	2020-08-31

Amy Burroughs

55 year

Audit Committee	2022-12-06
Compensation Committee

Catherine Stehman-Breen

63 year

Audit Committee

2019-06-27

Faraz Ali

53 year

Director/Board Member

2018-08-31

Latest Appointments: Tenaya Therapeutics, Inc.

Jun. 29	Tenaya Therapeutics, Inc. Announces Management Changes, Effective July 13, 2026	CI
Jan. 02	Tenaya Therapeutics, Inc. Announces Resignation of David Goeddel from Board and as A Member of All Committees, Effective January 26, 2026	CI
25-04-04	Kalaris Therapeutics, Inc. Appoints Leone Patterson to Its Board of Directors and as Chair of the Board?s Audit Committee	CI
25-02-07	Tenaya Therapeutics, Inc. Announces Tomohiro Higa as Interim Principal Accounting Officer	CI
24-12-17	Tenaya Therapeutics, Inc. Announces Resignation of Chihiro Saito as SVP, AFO and Interim PAO	CI
24-09-16	Tenaya Therapeutics, Inc. Announces Board Changes	CI
24-08-08	Faraz Ali to Serve as Interim Principal Financial Officer of Tenaya Therapeutics, Inc., Effective August 14, 2024	CI

More news

Former Officers and Directors: Tenaya Therapeutics, Inc.

Insider

Positions held

SinceUntil

David Goeddel

Director/Board Member	2024-12-31	2026-01-25
Chairman	2016-07-31	2024-12-31
Independent Dir/Board Member	2016-07-31	2026-01-25

Chihiro Saito

Comptroller/Controller/Auditor	-	2024-12-15
Corporate Officer/Principal	2024-07-31	2024-08-13

Leone Patterson

Director of Finance/CFO

2021-05-31

2024-08-13

Timothy Hoey

Chief Tech/Sci/R&D Officer

2017-07-31

2024-06-26

Jin Long Chen

Director/Board Member	2016-09-30	2024-06-24
Independent Dir/Board Member	2016-09-30	2024-06-24

Eli Casdin

Director/Board Member	2019-09-30	2022-12-30
Independent Dir/Board Member	2019-09-30	2022-12-30

Jeenjoo Kang

Director/Board Member	2016-07-31	2021-11-16
Independent Dir/Board Member	2016-07-31	2021-11-16

Benoit G. Bruneau

Founder

2015-12-31

Bruce R. Conklin

Founder

2015-12-31

Sheng Ding

Founder

2015-12-31

Saptarsi Haldar

Founder

2015-12-31

Eric Newell Olson

Founder

Sunita Sethi

General Counsel

Age distribution of managers

Parity Men Women

Male	12
Female	5

Of which Executive Committee

Male	6
Female	3

Of which Directors

Male	6
Female	2

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.

Employees

Sector

Biotechnology & Medical Research

More about the company